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Abstract
Background: Signal transduction processes mediated by phosphatidyl inositol phosphates affect a broad range of 
cellular processes such as cell cycle progression, migration and cell survival. The protein kinase AKT is one of the major 
effectors in this signaling network. Chronic AKT activation contributes to oncogenic transformation and tumor 
development. Therefore, analogs of phosphatidyl inositol phosphates (PIAs) were designed as new small drugs to 
block AKT activity for cancer treatment. Here we characterize the biological effects of the PIAs SH-5 and SH-6 in 
colorectal cancer cell lines.
Methods: Serum-starved or serum-supplemented human colorectal cancer cell lines SW480, HT29 and HCT116 were 
exposed to SH-5 and SH-6. AKT activation was determined by western blotting. Cell viability was assessed using a 
colorimetric XTT-based assay, apoptosis and cell cycle changes were monitored by FACS analysis. The dynamics of cell 
morphology alterations was evaluated by confocal and time-lapse microscopy. Transcriptional changes due to 
inhibitor treatment were analyzed using Affymetrix HG-U133A microarrays and RT-PCR.
Results: While the PIAs clearly reduce AKT phosphorylation in serum starved cells, we did not observe a significant 
reduction under serum supplemented conditions, giving us the opportunity to analyze AKT independent effects of 
these compounds. Both inhibitors induce broadly the same morphological alterations, in particular changes in cell 
shape and formation of intracellular vesicles. Moreover, we observed the induction of binucleated cells specifically in 
the SW480 cell line. Gene expression analysis revealed transcriptional alterations, which are mostly cell line specific. In 
accordance to the phenotype we found a gene group associated with mitosis and spindle organization down 
regulated in SW480 cells, but not in the other cell lines. A bioinformatics analysis using the Connectivity Map linked the 
gene expression pattern of the inhibitor treated SW480 cells to PKC signaling. Using confocal laser scanning 
microscopy and time lapse recording we identified a specific defect in the last step of the cytokinesis as responsible for 
the binucleation.
Conclusions: The PIAs SH-5 and SH-6 impinge on additional cellular targets apart from AKT in colorectal cancer cells. 
The effects are mostly cell line specific and have an influence at the outcome of the treatment. In view of potential 
clinical trials it will be necessary to take these diverse effects into consideration to optimize patient treatment.
Background
A wide variety of physiological processes is controlled by
sequestering regulatory proteins to specific membrane
domains. Derivates of phosphatidyl inositol play a crucial
role in this process. The inositol ring can be phosphory-
lated at the 3rd, 4th or 5th position, resulting in different
phosphatidyl inositol phosphates. During the last decades
the signal transduction processes mediated by the diverse
phosphatidyl inositol phosphates have been deciphered.
Phosphatidyl inositol(4,5)-bisphosphate (PI(4,5)P2) is
synthesized by type I (PIPKI) or type II (PIPKII) kinases
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using either phosphatidyl (4)-phosphate or phosphatidyl
(5)-phosphate as a substrate [1]. PI(4,5)P2 is an adaptor
for several proteins containing a PDZ domain, e.g. phos-
pholipase C (PLC), syntenin and the tight junction pro-
tein 1 (ZO-1), and is involved in the regulation of the
cytoskeleton [2], cytokinesis [3] and in the stabilization
and activation of integral membrane proteins such as
transporters and ion channels. Furthermore, PI(4,5)P2
can be either hydrolyzed to the secondary messengers
diacylglycerol (DAG) and inositol (1,4,5)-trisphosphate
(IP3), or further phosphorylated by PI3 kinases to phos-
phatidyl inositol (3,4,5)-trisphosphate (PI(3,4,5)P3), an
important activator of the AKT signaling pathway [4].
A great body of evidence suggests that the oncogenic
activation of AKT contributes to cellular transformation
and influences tumor development and progression [5-7].
Therefore, AKT is an interesting and promising target for
pharmacological intervention [8]. Several synthetic AKT
inhibitors like perifosine, GSK2110183, and RX-0201
entered phase I and II clinical trials. During the last years,
synthetic analogs of phosphatidyl inositol phosphates
(PIAs) were developed to block AKT activity in tumor
cells [9].
In our study, we used two synthetic phosphatidyl inosi-
tol phosphate analogs (SH-5 and SH-6), which lack the
hydroxyl group at position three of the inositol ring and
display modified aliphatic side chains conferring a higher
metabolic stability [9]. Previous cell culture studies have
suggested that the two compounds prevent AKT activa-
tion by interfering with its phosphatidyl inositol binding
domain and thereby induce apoptosis [10]. Most of the
experiments were done either under moderate serum
conditions (5%) or after serum starvation (0.1%) [11,12].
To mimic the conditions in tumors exhibiting a high
angiogenic activity, resulting in a growth factor-rich
micro-milieu, we decided to test the effects of PIAs under
s t a n d a r d  c o n d i t i o n s  i n  t h e  p r e s e n c e  o f  1 0 %  f e t a l  c a l f
serum. W e verified the inhibition of AKT in three col-
orectal cancer cell lines deprived of growth factors, but
did not observe a reduction of AKT activity under normal
cell culture conditions including fetal calf serum at stan-
dard concentration. Despite the missing effects on AKT
activity under full supplemented cell culture conditions,
we detected a broad range of morphological and tran-
scriptional alterations, indicating that these compounds
affect other sub cellular targets too. Most remarkably,
both compounds mediated a defect in the abscission, the
last step of cytokinesis, in the SW480 cells, resulting in
binucleation.
Results
The phosphatidyl inositol phosphate analogs SH-5 and SH-
6 induce morphological alterations in colorectal cancer 
cells
To study the biological effects of phosphatidyl inositol
phosphate analogs (PIA) on phosphoinositide dependent
signaling we chose three well established colorectal can-
cer cell lines as a model. First, because a large fraction of
colorectal cancer specimens and cell lines display muta-
tions of the PIK3CA gene (which codes for p110alpha, a
catalytic subunit of PI3K) and second, because colorectal
cancer specimens show increased PIP3 levels compared
to control tissues, both suggesting a pivotal role for phos-
phoinositide signaling in colorectal cancer [13,14].
SW480, HT29 and HCT116 cells harbor different kinds
of oncogenic mutations which reflect the common spec-
trum of alterations in colorectal cancers [15]. The cells
were serum starved for 24 hours, followed by treatment
with either DMSO or one of the phosphatidyl inositol
phosphate analogs (SH-5, SH-6) for two hours. We
observed a reduction of AKT phosphorylation in all of
the three cell lines, according to the proposed function of
the PIAs as AKT inhibitors (Figure 1A). A further incuba-
tion of the cells for 24 hours resulted in rounding up of
the cells and induction of cell death (Figure 1B).
In contrast, we did not observe any significant effect on
the phosphorylation status of AKT under cell culture
conditions including 10% fetal calf serum. Using two well
characterized PI3 kinase inhibitors as positive control, we
observed a strong reduction of AKT phosphorylation
after two hours of incubation under the same conditions.
Whereas wortmannin appeared to act transiently due to
rapid decay/inactivation, the effect of a single treatment
with LY294002 lasted for at least 48 hours in two of these
cell lines (Figure 2A).
Despite the lack of any clear effect of the PIAs on AKT
phosphorylation under normal serum conditions, we
observed clear morphological alterations of the treated
cells. In SW480 cells, SH-5 and SH-6 caused a spindle-
like morphology and increased cell scattering. The for-
mation of large cytoplasmic vesicles was prominent in the
HT29 and HCT116 cells (Figure 2B). For fully supple-
mented media conditions these findings suggest addi-
tional targets of the PIAs apart from AKT.
A genome-wide identification of transcriptional targets 
associated with SH-5 and SH-6 treatment
Our observations raised the question, which other targets
might be affected by the PIAs. Such targets might con-
tribute to anti-cancer treatment or unwanted side effects.
In order to identify additional targets of the PIAs, we per-
formed a genome-wide expression analysis of controlKrech et al. BMC Cancer 2010, 10:287
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cells and cells treated with the PI3-Kinase inhibitors or
PIAs for 48 hours. RNA was extracted as described in
methods and used to interrogate HG-U133A microar-
rays. We determined probesets of differentially expressed
genes (fold change > = 2) in comparison to the DMSO
control (Figure 3A). We identified a distinct set of target
genes of the PIAs specific for each cell line. In addition,
there is a partial overlap of genes down-regulated by SH-
6 between the SW480 and the HCT116 cells. Most of the
transcriptional alterations induced by the phosphatidyl
inositol analogs were found in the SW480 cells. We
observed only a limited number of transcriptional
changes in each cell line treated with wortmanin, consis-
tent with the observation, that wortmanin will be inacti-
vated within 48 hours. In contrast, we found a higher
number of differentially expressed genes after LY294002
treatment. The number of up-regulated genes compared
to the down-regulated genes is higher in HCT116 and
HT29 cells. Although AKT is active again in SW480 cells
after 48 hours of treatment with LY294002, the overall
number of regulated genes is higher than in the other two
cell lines. These transcriptional changes suggest a persis-
tent action of LY-294002 on SW480 cells, reshaping the
signaling network and thus finally leading to the reconsti-
tution of AKT-activity.
We performed an in silico analysis of the annotated bio-
logical features of differentially expressed genes (GO-
annotation) using Expander 4.0 [16] in order to find out
overrepresented functional groups of genes affected by
the PIAs (Additional file 1). A coordinated down-regula-
tion of genes associated with the mitotic cell cycle, espe-
cially M-phase, was peculiar to the SW480 cells treated
with SH-5 or SH-6 (Figure 3B). We verified the down reg-
ulation of four genes out of this group with RT-PCR (Fig-
ure 3C). Moreover, we found that genes linked to the
translational machinery and to cell migration were up-
regulated in the SW480 cells. The PIAs caused the up-
regulation of genes encoding components of the sterol,
isoprenoid and cholesterol metabolic process in HCT116
cells. Furthermore, we identified an overrepresentation of
genes involved in the immune response against viruses
among the up-regulated genes in the HT29 cells. In con-
trast to that, the number of over represented GO-terms
Figure 1 PIAs inhibit AKT phosphorylation after serum starva-
tion. (A) Western blot analysis of cells serum starved for 24 hours prior 
to incubation for two hours with SH-5 and SH-6, respectively. The 
phosphorylation status of AKT was determined using specific antibod-
ies. The detection of total AKT served as a loading control. (B) Morpho-
logical alterations induced in serum starved cells after 24 hours of 
treatment with SH-5 and SH-6, respectively. DMSO was used as a sol-
vent control.
Figure 2 PIAs did not reduce AKT activity under full supplement-
ed culture conditions. (A) Western blot analysis of colorectal cancer 
cells treated with either specific PI3 kinase inhibitors (LY294002, Wort-
mannin) or PIAs (SH-5, SH-6) for 2 and 48 hours, respectively. DMSO 
served as the solvent control. Levels of phosphorylated AKT were de-
termined using specific antibodies. Total AKT was determined as a 
loading control. (B) Morphological alterations induced by the PIAs after 
48 hours of treatment.Krech et al. BMC Cancer 2010, 10:287
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in the expression profiles of wortmanin or LY294002
treated cells was quite small (Additional file 1).
PIAs induce binucleation in SW480 cells
The treatment of the SW480 cells with PIAs resulted in a
down-regulation of a set of genes involved in the progres-
sion of the M-phase of the cell cycle and the organization
of the mitotic spindle. Therefore, we expected defects in
the progression of SW480 cells through this cell cycle
phase. We determined the proliferation rate of cells after
the SH-5 or SH-6 treatment using a colorimetric XTT-
assay. We observed only a small decrease in cell prolifera-
tion indicating that the down-regulation of target genes
affecting mitosis was insufficient to induce a cell cycle
block (Additional file 2A).
Accordingly, we did not obtain any evidence for the
induction of apoptosis by using FACS analysis (Addi-
tional file 2B).
Next we analyzed pretreated SW480 cells using confo-
cal laser scanning microscopy to reveal alterations
induced by the PIAs. We discovered a marked increase of
binucleated cells after treatment with SH-5 or SH-6, com-
pared to the vehicle-treated control population (Figure
4A, B). To characterize the mechanism underlying this
increase of binucleated cells we investigated the different
steps of the mitotic division. Cells were stained with anti-
bodies directed against γ-Tubulin, which is an integral
part of the centrosomes and with antibodies against pro-
tein regulator of cytokinesis 1 (PRC1). PRC1 colocalizes
with the mitotic spindle during metaphase (Figure 5A, B)
and relocalizes to the cleavage furrow in anaphase (Figure
5C, D). In the succeeding telophase, PRC1 is part of the
midbody between the emerging daughter cells (Figure 5E,
F). We did not detect any significant difference between
treated and control cells through-out these cell cycle
phases, suggesting that the defects must occur to a final
stage of cell division. In addition, we did not observe an
increasing number of chromosome bridges which might
explain the failure of nuclear division.
To better define the exact time course of cell cycle dis-
tortion, we performed time-lapse analysis of treated and
control cells. The cells regularly progressed through
mitosis until reaching the last step of cytokinesis (Figure
6A, Additional file 3). During this step, called abscission,
Figure 4 PIAs induce binucleation in SW480 cells. (A) Confocal La-
ser scanning images of cells treated with SH-5, SH-6 or DMSO. The 
green staining indicates Lamin A/C, the red Vimentin and the blue DA-
PI. (B) Percentage of binucleated cells determined microscopically af-
ter treatment with the indicated inhibitors or the DMSO control. The 
total number of cells was set to 100. Data sets were analyzed using the 
Student's t-Test. A p-value < 0.05 was considered as significant and 
marked by asterisks.
Figure 3 Distinct alterations of gene expression caused by the 
PIAs. (A) Graphical display of up- and down-regulated genes (fold 
change > = 2) after 48 hours of treatment with either the PI3kinase in-
hibitors or the PIAs. (B) Heatmap of probe sets which are associated 
with the mitotic cell cycle (GO-annotation GO:0000278) and down reg-
ulated in the SW480 cells by SH-5 and SH-6, respectively. (C) Verifica-
tion of down regulated genes in SW480 cells using RT-PCR.Krech et al. BMC Cancer 2010, 10:287
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the bridge between the daughter cells is normally dis-
rupted. PIA treated SW480 cells regularly performed
nuclear division and formed daughter cells initially. How-
ever, in contrast to the control cells, the intercellular
bridge remained stable for up to three hours with consec-
utive re-fusion, giving rise to binucleated cells (Figure 6B-
D, Additional files 4, 5 and 6). In summary these findings
demonstrate that the treatment with PIAs specifically
interferes with abscission in SW480 cells.
The PIA-mediated binucleation in SW480 cells is 
independent of a general PLC inhibition
Since AKT activity does not seem to be reduced signifi-
cantly by PIAs under normal serum condition, we looked
for other potential effector molecules. The phospholipase
C (PLC) binds to PI(4,5)P2 and hydrolyzes it to DAG and
IP3. PLC is localized at the cleavage furrow during cytoki-
nesis and is involved in the regulation of this process [17].
Therefore we hypothesized that the metabolically stable
PIAs might be able to bind to and inhibit PLC. We incu-
bated SW480 cells with the PLC inhibitor U73122 for 48
hours and fixed the cells as described above. We analyzed
the samples by confocal laser scanning microscopy after
staining them with anti-PRC1, anti-γ-Tubulin antibodies
and DAPI. We observed various defects during mitosis of
SW480 cells treated with U73122. These including
defects in forming the metaphase plate (Figure 7A), in
chromosome segregation (Figure 7B) and an increase in
the fraction of cells with chromosome bridges (Figure
7C). In addition to that, we detected differentially sized
daughter cells indicating defects during karyogenesis
(Figure 7D). However, in contrast to the PIAs, we did not
found any evidence for the induction of binucleated cells
after U73122 treatment. We conclude that the PIAs cause
binucleation by a mechanism independent of global PLC
activity.
A Connectivity Map analysis suggests the PKC signaling 
pathway as a PIA target
In order to find out more about the molecular basis of
binucleation in the SW480 cells, we took advantage of the
Connectivity Map (build 02), a web implemented data-
base of 6,100 gene expression profiles representing the
treatment of different cells with 1,309 bioactive com-
pounds of mostly known activity [18]. This database uses
a Kolmogorov-Smirnov test statistic to rank order the
6,100 individual treatment instances according to their
similarity to the user-provided signature of up- and
down-regulated genes. A detailed summary of this analy-
sis is shown in Additional files 7 and 8. Several of the top
ranking instances related to PIA-treatment of SW480
cells corresponded to treatments with compounds known
to interfere with the PIP2 (e.g. Resveratrol), the Ca2+ (e.g.
Thioridazine) or the PKC signaling (e.g. Rottlerin) (Figure
8A-D). Since PKC activity is depended on Diacylglycerol
(DAG), a product of the PIP2 hydrolyses, and Ca2+ levels,
these similarities hint at PKC signaling pathway as a
potential PIA target. Moreover, we found instances corre-
sponding to treatments with antagonists of the dopamine
receptor under the highest ranking candidates (e.g.
Prochlorperazine). Dopamine receptors are G-protein
coupled receptors which may also converge on the PKC
signaling pathway [19]. In order to prove if the treatment
Figure 5 Absence of visible mitotic defects in PIA-treated SW480 
cells. Fixed SW480 cells preincubated with either DMSO (A, C and E) or 
SH-6 (B, D and F) for 48 hours were stained with anti-PRC1 (red), anti-γ-
Tubulin (green) and DAPI (blue). We selected typical cells in different 
stages of the mitosis based on the DAPI staining: (A) and (B) cells in 
metaphase, (C) and (D) cells in anaphase, (E) and (F) cells in telophase 
(white arrows mark the midbodies).Krech et al. BMC Cancer 2010, 10:287
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with the suggested compounds results in a similar pheno-
type as with PIAs, we incubated SW480 cells for 48 hours
with Resveratrol and Rottlerin, respectively. Microscopic
analysis of treated cells revealed an increase of binucle-
ation with both compounds (Figure 8E).
Discussion
Genome-wide expression profiling of inhibitor-treated
colorectal cancer cells revealed some unexpected and
novel features of two synthetic AKT inhibitors. The most
remarkable alteration was the down-regulation of genes
associated with mitosis in the SW480 cell line, accompa-
nied by the induction of binucleation. Using confocal
laser scanning microscopy and time-lapse recordings, we
identified a specific defect during the abscission of the
daughter cells as the cause of binucleation. Perturbation
studies with pharmacological inhibitors suggested an
involvement of PKC signaling in this process.
Expression profiling of treated SW480 cells demon-
strated down-regulation of genes associated with mitosis.
The effect of this reduced gene expression on cell growth
was surprisingly weak, indicating that the remaining
expression of most of these genes was sufficient to allow
cell cycle progression. In addition, the XTT proliferation
assay is based on a metabolic process, in which the tetra-
zolium salt XTT is cleaved to form soluble colored for-
mazan. It is well established that metabolic activity is
highly correlated with the number of cells in the assay
(Roche). Since PIA-treated SW480 cells divide until the
last step of the abscission, they behave like two cells after
re-fusion regarding the metabolic activity. We assume
that binucleated cells retain this metabolic activity.
Despite the down-regulation of several genes associ-
ated with spindle formation and genes with critical func-
tions during mitosis, we observed no defects in the
mitosis until the last step of the abscission. The mitotic
spindle is not only implicated in chromosome segrega-
tion during mitosis but also affects the crucial steps of
cytokinesis. The central spindle complex concentrates
key regulators of the cytokinetic machinery, thus provid-
ing the basis for the final step of cell division. As spindle
assembly, chromosome segregation and cytokinesis
require complex protein interactions and possibly critical
thresholds of individual components, not necessarily
Figure 6 Time lapse recording revealed failures in abscission of PIA-treated SW480 cells. Time lapse recording was started 24 hours after the 
incubation of SW480 cells with either SH-6 or DMSO as a vehicle control. Images were made every 30 seconds and aligned to movies. The bright field 
images token out of the time lapse movies show dividing SW480 cells in the time from 24 to 48 hours after treatment. Control (A) as well as SH-6 
treated (B - D) cells progress similar through mitosis until cytokinesis. The daughter cells of the control samples will be separated during the cytokine-
sis, resulting in two individual cells (A). In contrast, the SH-6 treated cells fail to separate the bridge between the daughter cells, resulting in re-fusion 
and forming of binucleated cells (B - D). The time at the image corners is indicated in minutes.Krech et al. BMC Cancer 2010, 10:287
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reflected in mRNA levels, the deregulation of mitotic
spindle genes might affect cytokinesis without affecting
chromosomal segregation.
We validated the down-regulation of ASPM (abnormal
spindle homolog, microcephaly associated), NUSAP1
(nucleolar and spindle associated protein 1), PRC1 (pro-
tein regulator of cytokinesis 1) and CENPF (centromere
protein F (mitosin)) which are all necessary for proper
mitotic cell division. The NUSAP1 protein is localized at
the central spindle tubules during mitosis and gene
silencing by RNA interference resulted in defects of chro-
mosome segregation and cytokinesis [20,21]. ASPM is
located at the spindle poles or centrosomes during mito-
sis [22]. Mutations in ASPM are associated with auto-
somal recessive microcephaly as a consequence of
failures in the chromosome segregation. The knock-
down of CENPF with specific siRNA caused defects in
metaphase chromosome alignment, anaphase chromo-
some segregation and cytokinesis [23]. PRC1 encodes a
microtubule bundling protein with an essential function
in the formation of the contractile ring in the cleavage
furrow and in cytokinesis. The knock-down of PRC1
results in the induction of binucleated cells as a result of
defects during abscission [24,25]. In contrast to the
decreased RNA expression, we detected comparable lev-
els of PRC1 protein in immune fluorescence analysis of
treated and control cells, suggesting an additional control
at the level of translation or protein stability that might
compensate for transcriptional down-regulation. Based
on this observation we propose that PRC1 is not the
major cause of binucleation in our cell model. Since
expression profiling showed down-regulation of multiple
Figure 7 Induction of mitotic defects by the specific PLC inhibitor 
U73122. Fixed SW480 cells preincubated with the specific PLC inhibi-
tor U73122 for 48 hours were stained with anti-PRC1 (red), anti-γ-Tubu-
lin (green) and DAPI (blue). We selected typical cells in different stages 
of the mitosis based on the DAPI staining: (A) Cells in metaphase with 
defect metaphase plate, (B) Cells in anaphase with failure in chromo-
some segregation, (C) Cells in anaphase with chromosome bridge, (D) 
Cells in telophase, daughter cell nuclei have different size, indicating 
failure in chromosome segregation (the white arrow marks the mid-
body between the daughter cells).
Figure 8 Similarities of gene expression profiles in SW480 cells 
treated with PIAs and PKC signaling pathway inhibitors. (A) and 
(C) Each of the barviews is composed of 6100 individual treatment in-
stances from the Connectivity Map (build 02) database ranked accord-
ing to their similarity to the SH-5 or SH-6 gene signatures. The green 
area illustrate a positive, the red a negative and the gray field no enrich-
ment with the indicated signatures. Black lines corresponding to dis-
tinct individual instances of MCF7 cells treated with either Resveratrol 
(A) or Rottlerin (C). Please note, that all marked instances are among 
the top ranking in SW480 cells, whereas they are broadly distributed all 
over the barviews in the other cell lines. (B) and (D) The enrichment of 
PIA specific gene signatures is demonstrated for the best matched in-
dividual treatment instances. Gene probes which are induced (green) 
or repressed (red) by PIAs were ordered according to their differential 
expression in MCF7 cells caused by the treatment with Resveratrol and 
Rottlerin, respectively (x-axis). The running sum of the Kolomogorov-
Smirnov test is shown at the y-axis. Most genes which are induced by 
the PIAs appear early in the treatment profile, whereas the converse is 
true for repressed genes. (E) The treatment of SW480 cells with either 
Resveratrol or Rottlerin for 48 hours results in binucleated cells as de-
tected by DAPI staining.Krech et al. BMC Cancer 2010, 10:287
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mitosis-associated genes it is likely that the binucleation
in SW480 cells is a result of a multi-gene effect rather
than due to the perturbation of a single gene. The syn-
thetic compounds SH-5 and SH-6 used in our study are
thought to work as competitive inhibitors of the naturally
occurring phosphatidyl inositol phosphates by sequester-
ing inactive AKT in the cytoplasm and preventing its
translocation to the membrane. Therefore it is likely, that
the efficiency of these analogs depends on the amount of
endogenous PI(4,5)P2 and PI(3,4,5)P3. Under normal cell
culture conditions a broad range of growth factors stimu-
late signaling pathways, resulting in an increase of
PI(3,4,5)P3 [26]. Our experiments suggest that the applied
concentrations of SH-5 and SH-6 are not sufficient to
inhibit the phosphorylation of AKT efficiently in three
colorectal cancer cell lines in this context. However, since
both compounds have strong structural similarities to
PI(4,5)P2, they may interact with targets distinct from
AKT, e.g. PLC. PLC isoforms are localized to the cleavage
furrow and may be involved in the control of the progres-
sion through cytokinesis by regulating local PI(4,5)P2 lev-
els [17]. Based on the different cellular effects of the
specific PLC inhibitor U73122, we conclude that the PIA-
induced binucleation is independent on global PLC activ-
ity. Nevertheless we cannot exclude the possibility that
SH-5 and SH-6 alter the sub cellular localization of PLC
during cytokinesis, resulting in a disorganization of the
PI(4,5)P2 dependent signaling.
Gene expression signatures derived from PIA-treated
SW480 cells have a high similarity to those observed in
MCF7 cells treated with PKC signaling pathway inhibi-
tors. The PKC protein family consists of at least 10 ser-
ine/threonine protein kinases which are involved in the
control of a wide variety of cellular processes. Activation
of PKCs is mediated by diacylglycerol (DAG), Ca 2+ and
PDK1, which are influenced by the PI(4,5)P2 levels [27]. It
was shown that resveratrol inhibits the polyphospho-
inositide metabolism in activated platelets resulting in a
decrease of the PI(4,5)P2 level [28]. We therefore suppose
that a similar mechanism contributes to the perturbation
of PI(4,5)P2 levels in SW480 cells, followed by a decreased
PKC activity. Rottlerin is a known inhibitor of PKC δ,
pointing at a special role of this isoform during cytokine-
sis in SW480 cells. Interestingly, we recognized a more
than two-fold mRNA expression of PKC δ in SW480 cells
as compared to the other cell lines. We can speculate that
this expression difference may be partially responsible for
the different sensitivity of the cell lines to the treatment
with the PIAs.
In this context it is also interesting that the response of
SW480 cells to long term LY294002 treatment is different
compared to the two other cell lines both at the transcrip-
tional and phenotypic level. Whereas the phosphoryla-
tion of AKT was strongly inhibited in 2 hours, it was re-
phosphorylated within 48 hours. Experiments with con-
ditioned culture medium exclude the possibility that
LY294002 decayed during this time. Even after 48 hours
the remaining LY294002 in the culture medium was suffi-
cient to block AKT phosphorylation in prior untreated
SW480 cells within two hours (data not shown). It is also
remarkable that we detected more transcriptional altera-
tions in the SW480 cells as in the two other cell lines. In
contrast to SW480 cells, HT29 and the HCT116 harbor
an oncogenic mutation in the PIK3CA gene resulting in
an increased PI3 kinase activity. This may compensate for
the effects caused by SH-5 and SH-6 [29].
Conclusions
Due to its multiple functions and oncogenic potential
AKT is a promising target for pharmacologic interven-
tion in cancer therapy. The design of phosphoinositide
analogues represents a targeted approach towards this
issue. Our study characterizes the actions of two phos-
phoinoistide analogues (SH-5 and SH-6) in human col-
orectal cancer cell lines. Independent of AKT inhibition
SH-5 and SH-6 interfered with important cellular func-
tions contributing to the outcome of the treatment.
Methods
Cell lines and cell culture
SW480, HT29 and HCT116 cells were cultured in com-
plete L-15 medium at 37°C and 5% CO2 in a humified
incubator. Following chemical compounds were used for
treament: LY-294002 (20 μM; Alexis Deutschland GmbH,
Grünberg, Germany), Wortmannin (1 μM; Sigma) , SH-5
(10 μM; Alexis Deutschland GmbH, Grünberg, Ger-
many), SH-6 (10 μM; Alexis Deutschland GmbH, Grünb-
erg, Germany), U73122 (1, 3 and 10 μM; Merck KGaA,
Darmstadt, Germany), Rottlerin and Resveratrol (10 μM
and 50 μM, respectively; (Calbiochem) Merck KGaA,
Darmstadt, Germany). DMSO served as a negative con-
trol unless otherwise specified. The DMSO content of the
different experiments was adjusted to a final concentra-
tion of 0,29%. Cells were treated for 2 hours, 48 hours or
72 hours.
Immunoblots
Cells were lysed at the corresponding time points using
SDS-lysis buffer (1% SDS, 10 mM Tris-HCl pH 7.5, 2 mM
EDTA pH 8). 10 μg of protein of whole cell lysates per
lane were fractionated by SDS-PAGE and blotted onto
nitrocellulose membranes (Schleicher & Schuell Biosci-
ence GmbH, Dassel, Germany). Following primary anti-
bodies were used: AKT (polyclonal, Cell Signaling
Technology Inc., Beverly, USA), Phospho-AKT (phos-
pho-Serine 473; polyclonal; Cell Signaling), and beta-
actin (Santa Cruz Biotechnology, Inc., Santa Cruz, USA).Krech et al. BMC Cancer 2010, 10:287
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For protein detection secondary antibodies coupled to
horseradish peroxidase (Cell Signaling Technology Inc.,
Beverly, USA) and ECL (Amersham Biosciences Europe
GmbH, Freiburg, Germany) were applied.
Cell proliferation
Cells were treated for 24 hrs, 48 hrs and 72 hrs with the
inhibitors or DMSO. Cell proliferation was assessed at
the corresponding time points using the colorimetric
XTT-assay (Roche Diagnostics GmbH, Mannheim, Ger-
many) according to the manufacturer's protocol. The
extinction measurements were calculated relative to the
negative control at 72 hrs. The means of three indepen-
dent experiments are presented.
Fluorescence activated cell sorting (FACS)
Both adherent and floating cells were collected after 48
hrs of treatment and washed twice in phosphate-buffered
saline, then fixed overnight using 70% ethanol. Following
centrifugation the supernatant was discarded and the cell
pellet was resuspended in dilution buffer (0.1% Triton X
100, 0.5% BSA in phosphate buffered saline, supple-
mented with 80 μg/ml RNase (RNase, DNase free; Roche
Diagnostics GmbH, Mannheim, Germany)). Samples
were kept at room temperature for 30 min. and then cen-
trifuged. The supernatant was discarded and cells were
stained with 20 μg/ml propidium iodide (Fluka, Heidel-
berg, Germany) in dilution buffer. Samples were analysed
by flow cytometry (FACS Calibur System; BD Biosci-
ences, Heidelberg, Germany). Fragments of damaged or
apoptotic cells were determined as pre-G1 fraction using
WinMDI (WinMDI V. 2.8; Joseph Trotter; freeware). All
experiments were performed in triplicate.
RNA extraction and purification
Following inhibitor-treatment for 48 hours cells were
washed twice with ice-cold phosphate buffered saline
supplemented with diethylpyrocarbonate and then lysed
using Trizol (Invitrogen). The suspension was transferred
to a new tube and chloroform was added at a ratio of 1:6.
After mixing thoroughly the suspension was centrifuged
for 15 min. at 8°C at 12.000 G. The interphase was trans-
ferred to fresh tube and an equivalent amount of isopro-
panol was added. The suspension was inverted several
times. Following 10 min. at room temperature samples
were centrifuged for 15 min. at 4°C at 12.000 G. The
supernatant was discarded, the pellet washed twice with
75% ice-cold ethanol and then dissolved in RNase free
water. RNA extracts were further purified using RNeasy-
Kit (Qiagen) according to the manufacturer's clean-up
protocol.
Microarray analysis
The human arrays HG-U133A (Affymetrix, Santa Clara,
CA, USA) comprised a set of 22,283 known genes. Label-
ling of RNA targets, hybridization and post-hybridization
procedures were performed according to protocols pro-
vided by Affymetrix; quality control of RNA extracts was
performed using Test-3-Chips (Affymetrix, Santa Clara,
CA, USA). Following washing and staining, probe arrays
were scanned twice at 3 μm resolution using a confocal
scanner with argon laser instrument (Hewlett-Packard,
Santa Clara, CA, USA), controlled by Microarray Suite
5.0 software (Affymetrix). Photoemission was detected
by a photomultiplier tube through a 570-nm long pass fil-
ter. Computer-generated array images were overlaid with
a virtual grid controlled by Microarray Suite 5.0 software
(Affymetrix, Santa Clara, CA, USA). This step allowed
definition of each feature and alignment within known
array dimensions. About 40 pixels within each feature
were averaged after discarding outliers and pixels near
feature boundaries. Gene expression levels were calcu-
lated according to the average hybridization intensities of
perfectly matched versus mismatched oligonucleotide
probes. Arrays were scaled to by Microarray Suite 5.0
software to an average intensity of 2,500 per gene and
analyzed independently. Probe sets were either marked
absent or present according to their signal intensity and
quality of hybridisation. Probe sets which were marked
absent in all array experiments were excluded from fur-
ther analysis. Probe sets which showed at least two fold
change in intensity compared to DMSO control were
considered up regulated or down regulated respectively.
Microarray data are available at the GEO database
http://www.ncbi.nlm.nih.gov/ under the accession num-
ber GSE18005.
RT-PCR
Transcript sequences were obtained from NCBI Entrez
Nucleotide http://www.ncbi.nlm.nih.gov/entrez. Primers
were designed using primer-3-input http://frodo.
wi.mit.edu/primer3/. Primer sequences were checked for
unspecific overlap with other transcripts using NCBI
Blast http://www.ncbi.nlm.nih.gov/BLAST. To identify
unwanted amplification of genomic DNA by product size,
primers were checked with Ensembl http://www.
ensembl.org/index.html to span introns. Selected primers
were synthesized by MWG Biotech (Berlin, Germany).
Rt-PCR was performed using Access RT-PCR-Kit (Pro-
mega) using 4 ηg of purified RNA. Products were frac-
tioned using agarose gel electrophoresis with
ethidiumbromide. Products were analysed under UV-
light. Primer sequences and reaction conditions are listed
below (see Table 1)Krech et al. BMC Cancer 2010, 10:287
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Fluorescence microscopy
Cells were seeded on cover slides and treated with the
inhibitors for 48 hrs. Cells were then washed twice with
ice-cold phosphate buffered saline and fixed with pre
chilled acetone/methanol (1:1) at -20°C. The cells were
pre incubated in PBS containing 1.5% horse serum to
block non-specific binding of antibodies. The same buffer
was used for all incubation steps. We used the following
antibodies for staining of the cells: anti-lamin A/C, anti-
vimentin, anti-PRC1 and anti-γ-Tubulin (all: Santa Cruz
Biotechnology, Inc., Santa Cruz, USA). In order to detect
the DNA we included DAPI (Sigma, Germany) in the last
incubation step. Bound antibodies and stained DNA were
detected using a confocal laser scanning microscope
from Leica (DM IRBE). For quantification of binucle-
ation, 200-300 nuclei per sample were counted. Three
independent experiments were performed, each counted
by at least two independent, blinded investigators and the
means are presented.
Time lapse recording
We used the Biozero microscope from Keyence (Neu-
Isenburg, Germany) equipped with a time lapse unit. We
started 24 hours after adding the PIAs or DMSO to take
pictures every 30 seconds. Pictures were aligned to a
movie with a frequency of 25 pictures per second using
the free software JPGVideo (NDW Ltd., Nottingham,
England). Cutting and cropping of the movies were done
with the free software VirtualDub 1.8.8.
Statistical analysis
Statistical analysis of the number of binucleated cells was
performed using Students t-Test. A p-value < 0.05 was
considered significant. For the GO analysis, we used the
implemented statistical features of Expander 4.0 with an
adjusted p-value < 0.05.
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Table 1: Primer sequences and  reaction conditions
primer sequence Ta* product 
size
GAPDH L 5' - CGACCACTTTGTCAAGCTCA - 3' 56°C 205 bp
GAPDH R 5'- AGGGGTCTACATGGCAACTG - 3' 56°C
ASPM L 5' - CAGTGATGTCACAGGGTTGG - 3' 54°C 272 bp
ASPM R 5' - CTCGTGAAAAAGCCAAAAGG - 3' 54°C
CENPF L 5' - GCCCATATATCCTGCGAAGA - 3' 56°C 258 bp
CENPF R 5' - GGCTGTCAGTCGGACTTCTC - 3' 56°C
NUSAP1 L 5' - TGTGCTTGGGACACACAAAT - 3' 54°C 297 bp
NUSAP1 R 5' - CGTTTCTTCCGTTGCTCTTC - 3' 54°C
PRC1 L 5' - ACAAAGGCTTCTAGGCGTGA - 3' 56°C 290 bp
PRC1 R 5' - GTGGCCACAGCTTCTCTTTC - 3' 56°C
*annealing temperatureKrech et al. BMC Cancer 2010, 10:287
http://www.biomedcentral.com/1471-2407/10/287
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